Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

EXHIBIT 10.1    
    

SIXTH AMENDMENT AND CONSENT TO SECOND AMENDED

AND RESTATED CREDIT AGREEMENT  

        THIS SIXTH AMENDMENT AND CONSENT TO SECOND AMENDED AND RESTATED CREDIT AGREEMENT, dated as of June 1, 2004 (this
"Amendment"), to the Second Amended and Restated Credit Agreement, dated as of September 30, 2003 (as amended, supplemented or otherwise modified
from time to time, the "Credit Agreement"), by and among General Electric Capital Corporation, as Agent and Lender
("Agent"), Inverness Medical Innovations, Inc. ("Innovations"), Wampole Laboratories, Inc.
and Inverness Medical (UK) Holdings Limited, as borrowers ("Borrowers"), the other Credit Parties signatory thereto, Merrill Lynch Capital, a division
of Merrill Lynch Business Financial Services Inc., as documentation agent, co-syndication agent and lender, UBS Securities LLC, as co-syndication agent, and the lenders
signatory thereto from time to time (collectively, the "Lenders") and Amendment to the Post-Closing Letter to the Credit Agreement dated
January 20, 2004 (as amended, the "Post-Closing Letter"). 

WITNESSETH  

        WHEREAS, Borrowers have notified Agent that Inverness Medical Switzerland GmbH ("Swissco") desires to acquire,
through a newly acquired wholly-owned subsidiary of Swissco organized in Germany ("Acquisition Newco"), one hundred percent (100%) of the issued and
outstanding equity interests of (i) Viva Diagnostika—Diagnostische Produkte—GmbH ("Viva") from Bernd Stammel, Susanne
Stammel, Dr. Willi Wegst, Gerda Wegst, Dr. Heinz-Peter Nachreiner and Gabriele Beutler-Nachreiner (collectively, the "Viva Stockholders"),
and (ii) DMD, Dienstleistungen & Vertrieb fûr Medizin und Diagnostik GmbH ("DMD") from the Viva Stockholders and DMD AG, a
German corporation (collectively, the "Selling Stockholders"), in each case pursuant to a purchase agreement. The purchase of Viva and DMD are
collectively referred to herein as the "Viva and DMD Purchase"; 

        WHEREAS,
the Viva and DMD Purchase is not a Permitted Acquisition (as defined in the Credit Agreement) and therefore is prohibited under  Section 6.1 of the Credit Agreement; 

        WHEREAS,
the acquisition of Acquisition Newco is prohibited under Section 6.1 of the Credit Agreement; 

        WHEREAS,
a portion of each purchase price shall be paid in the form of shares of stock of Inverness Medical Innovations, Inc.
("Innovations") and the issuance of such shares by Innovations is prohibited under Section 6.5 of
the Credit Agreement; 

        WHEREAS,
the Borrowers have notified the Agent that Scandinavian Micro Biodevices Aps ("SMB") desires to purchase approximately 27% of the
outstanding equity of a newly formed entity ("Investment Newco") in exchange for the contribution by SMB of its rights in and to that certain Danish
patent application (#PA 2003-01764) (the "Patent") to Investment Newco (the "U.C. Light
Investment"); 

        WHEREAS,
the purchase of equity of Investment Newco is prohibited by Section 6.2 of the Credit Agreement; 

        WHEREAS,
the contribution by SMB of its rights in and to the Patent is prohibited by Section 6.8 of the Credit Agreement; 

        WHEREAS,
Borrowers have notified Agent that Inverness Medical Innovations, Inc. ("Innovations"), through a newly formed
wholly-owned subsidiary ("Merger Newco"), desires to acquire one hundred percent (100%) of the issued and outstanding stock of Advantage Diagnostics
Corporation ("ADC") by way of a merger (the "ADC Merger") with or into Merger Newco in exchange for
consideration of $2,500,000 in cash, pursuant to which Merger Newco shall be the surviving entity; 

 

        WHEREAS,
pursuant to the letter of intent signed by Innovations, Innovations shall also pay $1,500,000 to ADC's current stockholders as additional compensation for the merger upon proof
of feasibility of the ADC HIV test (the "Additional Merger Compensation"); 

        WHEREAS,
the ADC Merger is not a Permitted Acquisition and therefore is prohibited under Section 6.1 of the Credit Agreement; 

        WHEREAS,
the formation of Merger Newco is prohibited under Section 6.1 of the Credit Agreement; 

        WHEREAS,
Borrowers have notified Agent that Inverness Medical (UK) Holdings, Ltd ("Inverness UK") desires to acquire one hundred
percent (100%) of the issued and outstanding equity interest of IV Diagnostics Limited, a holding company formed under the laws of the United Kingdom ("IV
Diagnostics") from Dror Yeffet and Mihal Jacobi (the "IV Diagnostics Purchase" and together with the Viva and DMD Purchase, the
U.C. Light Investment and the ADC Merger, the "Proposed Transactions"); 

        WHEREAS,
Borrowers have requested that Agent and Requisite Lenders consent to the Proposed Transactions on the terms and conditions set forth herein; and 

        WHEREAS,
Agent and Requisite Lenders have agreed to amend the Credit Agreement and the Post-Closing Letter, in the manner, and on the terms and conditions, provided for
herein. 

        NOW
THEREFORE, in consideration of the premises and for other good and valuable consideration, the receipt, adequacy and sufficiency of which are hereby acknowledged, the parties hereto
agree as follows: 

        1.    Definitions.    Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the
Credit Agreement. 

        2.    Consent to Acquisition of Acquisition Newco.    As of the Effective Date (as defined below), Agent and Requisite
Lenders hereby agree that the consummation of the purchase of Acquisition Newco shall not create a breach under Sections 6.1 of the Credit Agreement,  provided that (a) the purchase price paid by or on behalf of Swissco for Acquisition Newco shall not exceed €30,000,
(b) Acquisition Newco shall have assets consisting of at least €25,000 (the "Assets") at the time of such acquisition,
(c) Acquisition Newco shall have no property or other assets, other than the Assets, (d) no Credit Party shall transfer any funds or assets (other than funds or assets necessary to pay
the purchase price in connection with the Viva and DMD Purchase, which funds or assets shall in no event exceed the Viva and DMD Purchase Price (as defined below)) to Acquisition Newco prior to the
consummation of the Viva and DMD Purchase, and (e) Acquisition Newco shall not conduct any business prior to the consummation of the Viva and DMD Purchase. 

        3.    Consent to Viva and DMD Purchase.    As of the Effective Date, Agent and Requisite Lenders hereby agree that the
consummation of the Viva and DMD Purchase shall not create a breach under Sections 6.1 or 6.5 of the
Credit Agreement, provided that: 

        (a)   (i) Agent
shall have received evidence satisfactory to Agent that each of the conditions precedent to a Permitted Acquisition set forth in  Section 6.1(i)—(xi) of the Credit Agreement have been satisfied
in connection with the Viva and DMD Purchase (other than the
conditions set forth in Section 6.1(i), Section 6.1(v),  Section 6.1(viii) and Section 6.1(ix) which are hereby waived, provided that
(A) the Credit Parties do not expend any cash in connection with the Viva and DMD Purchase other than for costs and expenses and cash payments to the Selling Stockholders and or DMD AG which do
not exceed (x) €2,821,000 in the aggregate with respect to the Viva and DMD Purchase (the "Viva and DMD Purchase Price"), and
(B) all Indebtedness, Guaranteed Indebtedness, contingent obligations and other liabilities (other than ordinary course trade payables) of each of Viva and DMD incurred, assumed or otherwise
reflected on the consolidated 

2

 

balance
sheet of Borrowers and each of Viva and DMD after giving effect to such Viva and DMD Purchase are paid, and all Liens (other than Permitted Encumbrances) on the assets and stock of each of
Viva and DMD are terminated, concurrently with the consummation of the Viva and DMD Purchase), and (ii) within thirty (30) days after the consummation of the Viva and DMD Purchase, each
of Viva and DMD shall grant a first priority perfected security interest (subject to Permitted Encumbrances) in all of its respective assets to secure the Obligations of the European Credit Parties
and execute all documents and take all actions (including obtaining landlord waivers in form and substance reasonably satisfactory to Agent) requested by Agent in connection therewith; 

        (b)   Within
thirty (30) days after the consummation of the Viva and DMD Purchase, Agent shall have received (i) a Guaranty and Joinder Agreement, in each case,
in form and substance satisfactory to Agent, pursuant to which each of Acquisition Newco, Viva and DMD agrees to guarantee the Obligations of the European Credit Parties under the Loan Documents and
become a party to the Loan Documents; (ii) a Pledge Agreement (the "Viva and DMD Pledge Agreement"), in form and substance satisfactory to Agent,
pursuant to which Acquisition Newco pledges one hundred percent (100%) of the issued and outstanding equity interest of each of Viva and DMD (the "Pledged
Stock") to Agent, in each case duly executed and delivered by an authorized officer of Viva, DMD and/or Acquisition Newco, as applicable; and (iii) a Pledge Agreement or
a pledge amendment (the "Acquisition Newco Pledge Agreement"), in form and substance satisfactory to Agent, pursuant to which Swissco pledges one
hundred percent (100%) of the issued and outstanding equity interest of Acquisition Newco (the "Acquisition Newco Stock") to Agent, duly executed by an
authorized officer of Acquisition Newco or Swissco, as applicable; 

        (c)   Within
thirty (30) days after the consummation of the Viva and DMD Purchase, Agent shall have received original certificates, if any, representing the Pledged
Stock pledged by Acquisition Newco pursuant to the terms of the Viva and DMD Pledge Agreement; 

        (d)   Within
thirty (30) days after the consummation of the Viva and DMD Purchase, Agent shall have received an original certificate, if any, representing the
Acquisition Newco Stock pledged by Swissco pursuant to the terms of the Acquisition Newco Pledge Agreement; 

        (e)   Within
thirty (30) days, or such longer period as Agent may consent to in its sole discretion, after the consummation of the Viva and DMD Purchase, Agent shall
have received tri-party blocked account agreements, in form and substance reasonably satisfactory to Agent, duly executed and delivered by each of Acquisition Newco, Viva and DMD and each
bank where Acquisition Newco, Viva or DMD has established a deposit or disbursement account (other than payroll accounts), in each case in accordance with the requirements set forth in  Section 1.8
and Annex C of the Credit Agreement; 

        (f)    Agent
shall have received (x) updated Schedules 3.1, 3.2, 3.6, 3.7, 3.8, 3.15, 3.19 and  5.1 to the Credit Agreement and (y) a revised Exhibit A-1 updated to include
Material Contracts, if any, to which any of Acquisition Newco, Viva or DMD is a party, each in form and substance satisfactory to Agent, after giving pro forma effect to the Viva and DMD Purchase; 

        (g)   Agent
shall have received a copy of each of Viva's and DMD's (i) charter documents and all amendments thereto and (ii) good standing certificates or the
foreign equivalent and certificates of qualification to conduct business in each jurisdiction where its ownership or lease of property or the conduct of its business requires such qualification, each
dated a recent date and certified by the applicable authorized Governmental Authority; 

        (h)   Agent
shall have received a copy of each of Viva's and DMD's (i) bylaws and all amendments thereto and (ii) resolutions of each of Viva's and DMD's Board
of Directors and, to the extent required under applicable law, stockholders, approving and authorizing the execution, 

3

 

delivery
and performance of the Loan Documents to which Viva or DMD is, or will be, a party and the transactions to be consummated in connection therewith, each certified by an authorized officer of
each of Viva and DMD (after giving effect to the Viva and DMD Purchase) as being in full force and effect without any modification or amendment; 

        (i)    Agent
shall have received a copy of Acquisition Newco's (i) bylaws and all amendments thereto and (ii) resolutions of Acquisition Newco's Board of
Directors and, to the extent required under applicable law, stockholders, approving and authorizing the execution, delivery and performance of the purchase agreements with respect to the Viva and DMD
purchase and the Loan Documents to which Acquisition Newco is, or will be, a party and the transactions to be consummated in connection therewith, each certified by Acquisition Newco's corporate
secretary or an assistant secretary (after giving effect to the Viva and DMD Purchase) as being in full force and effect without any modification or amendment; 

        (j)    Agent
shall have received a signature and incumbency certificate of the officers of each of Acquisition Newco, Viva and DMD, certified by a managing director or other
officer of each of Acquisition Newco, Viva and DMD (after giving effect to the Viva and DMD Purchase) as being true, accurate, correct and complete in all respects; 

        (k)   Agent
shall have received executed copies of purchase agreements executed in connection with the Viva and DMD Purchase, together with all amendments thereto, and all
documentation delivered in connection therewith (all in form and substance satisfactory to Agent), certified by an authorized officer of Acquisition Newco to be true and complete and in full force and
effect as of the Effective Date; 

        (l)    Within
thirty (30) days after the consummation of the Viva and DMD Purchase, Agent shall have received a legal opinion of counsel acceptable to Agent (subject to
customary qualifications) which shall provide (i) that the Loan Documents have been duly authorized, executed and delivered by, and are enforceable against, Acquisition Newco, Viva and DMD,
(ii) that the Viva and DMD Purchase was approved by all requisite corporate action by Acquisition Newco and (iii) such other opinions as Agent may reasonably request, all in form and
substance satisfactory to Agent; 

        (m)  Upon
Agent's request, Agent shall have received, within thirty (30) days after the consummation of the Viva and
DMD Purchase, a copy of the Assignment of Representations and Warranties, duly executed by an authorized officer of Acquisition Newco and acknowledged by the Selling Stockholders; 

        (n)   Within
thirty (30) days after the consummation of the Viva and DMD Purchase, Agent shall have received evidence that CT Corporation has been appointed as agent
for service of process for each of Acquisition Newco, Viva and DMD; and 

        (o)   The
Viva and DMD Purchase shall have been consummated on or prior to July 30, 2004. 

        4.    Consent to U.C. Light Investment.    As of the Effective Date, (i) Agent and Requisite Lenders hereby
consent to the transfer by SMB of its interest in and to the Patent to Investment Newco; (ii) Agent hereby releases its Lien on the Patent and agrees to execute and deliver to Borrowers
UCC-3 amendments and/or any other releases reasonably requested by Borrowers and at Borrowers' expense, and (iii) Agent and the Requisite Lenders agree that the consummation of the
U.C. Light Investment on the terms and conditions set forth in the Subscription Agreement shall not create a breach under Sections 6.8 of the Credit
Agreement; provided that, so long as no adverse consequences as a result of financial assistance would result therefrom, within thirty (30) days of the Effective Date Agent shall have received
a Pledge Agreement or a pledge amendment (the "Investment Newco Pledge Agreement"), in form and substance satisfactory to Agent, pursuant to which SMB
pledges its interest in the issued and outstanding equity of Investment Newco to Agent, duly executed and delivered by an 

4

 

authorized
officer of SMB, together with, to the extent that SMB's equity interest of Investment Newco pledged by SMB pursuant to the terms of the Investment Newco Pledge Agreement has been
certificated, an original certificate representing said equity interest. 

        5.    Consent to ADC Merger.    As of the Effective Date, Agent and Requisite Lenders hereby agree that the
consummation of the ADC Merger shall not create a breach under Sections 6.1 of the Credit Agreement,  provided that: 

        (a)   (i) Agent
shall have received evidence satisfactory to Agent that each of the conditions precedent to a Permitted Acquisition set forth in  Section 6.1(i)—(xi) of the Credit Agreement have been satisfied
in connection with the ADC Merger (other than the conditions set
forth in Section 6.1(i), Section 6.1(v),  Section 6.1(vi) and Section 6.1(ix) which are hereby waived, provided that (A) the
Credit Parties do not expend any cash in connection with the ADC Merger other than for costs and expenses and cash payments to the selling stockholders of ADC which do not exceed (x) $2,800,000
in the aggregate with respect to consummation of the ADC Merger and (y) the Additional Merger Compensation and (B) all Indebtedness, Guaranteed Indebtedness, contingent obligations and
other liabilities (other than ordinary course trade payables) of ADC incurred, assumed or otherwise reflected on the consolidated balance sheet of Borrowers and Merger Newco after giving effect to
such ADC Merger are paid, and all Liens (other than Permitted Encumbrances) on the assets and stock of Merger Newco are terminated, concurrently with the consummation of the ADC Merger), and
(ii) Merger Newco shall grant a first priority perfected security interest (subject to Permitted Encumbrances) in all of its respective assets to secure the Obligations of the Credit Parties
and execute all documents and take all actions (including obtaining landlord waivers in form and substance reasonably satisfactory to Agent) requested by Agent in connection therewith; 

        (b)   Agent
shall have received (i) a Guaranty and Joinder Agreement, in each case, in form and substance satisfactory to Agent, pursuant to which Merger Newco agrees
to guarantee the Obligations of the Credit Parties under the Loan Documents and become a party to the Loan Documents; (ii) a Pledge Agreement or a pledge amendment (the
"Innovations Pledge Agreement"), in form and substance satisfactory to Agent, pursuant to which Innovations pledges one hundred percent (100%) of the
issued
and outstanding equity interest of Merger Newco (the "Merger Newco Stock") to Agent, duly executed by an authorized officer of Innovations; 

        (c)   Agent
shall have received an original certificate representing the Merger Newco Stock pledged by Innovations pursuant to the terms of the Innovations Pledge Agreement; 

        (d)   Within
thirty (30) days, or such longer period as Agent may consent to in its sole discretion, after the consummation of the ADC Merger, Agent shall have received
tri-party blocked account agreements, in form and substance reasonably satisfactory to Agent, duly executed and delivered by Merger Newco and each bank where Merger Newco has established a
deposit or disbursement account (other than payroll accounts), in each case in accordance with the requirements set forth in Section 1.8 and  Annex C
of the Credit Agreement; 

        (e)   Agent
shall have received (x) updated Schedules 3.1, 3.2, 3.6, 3.7, 3.8, 3.15, 3.19 and  5.1 to the Credit Agreement and (y) a revised Exhibit A-1 updated to include
Material Contracts, if any, to which Merger Newco is a party, each in form and substance satisfactory to Agent, after giving pro forma effect to the ADC Merger; 

        (f)    Agent
shall have received a copy of each of (i) Merger Newco's and ADC's charter documents and all amendments thereto and (ii) good standing certificates
or the foreign equivalent and certificates of qualification to conduct business in each jurisdiction where their respective ownership or lease of property or the conduct of its business requires such
qualification, each dated a recent date and certified by the applicable authorized Governmental Authority; 

5

 

        (g)   Agent
shall have received a copy of (i) each of Merger Newco's and ADC's bylaws and all amendments thereto (ii) resolutions of Merger Newco's and ADC's
Board of Directors and, to the extent required under applicable law, stockholders, approving and authorizing the ADC Merger and the execution, delivery and performance of the transaction documents to
be executed in connection with the ADC Merger, and (iii) resolutions of Merger Newco's Board of Directors and, to the extent required under applicable law, stockholders, approving and
authorizing the Loan Documents to which Merger Newco will be a party, each certified by an authorized officer of Merger Newco as being in full force and effect without any modification or amendment in
the case of clauses (i) and (ii) immediately prior to the effective time for the ADC Merger, and in the case of clause (iii) as of the Effective Date; 

        (h)   Agent
shall have received a signature and incumbency certificate of the officers of each of Merger Newco, certified by Merger Newco's corporate secretary or an assistant
secretary as being true, accurate, correct and complete in all respects; 

        (i)    Agent
shall have received executed copies of the agreement and plan of merger executed in connection with the ADC Merger, together with all amendments thereto, and all
documentation delivered in connection therewith (all in form and substance satisfactory to Agent), certified by an authorized officer of Merger Newco to be true and complete and in full force and
effect as of the Effective Date; 

        (j)    Agent
shall have received a legal opinion of counsel acceptable to Agent (subject to customary qualifications) which shall provide (i) that the Loan Documents
have been duly authorized, executed and delivered by, and are enforceable against Merger Newco, (ii) that the ADC Merger was approved by all requisite corporate action by Merger Newco and ADC
and (iii) such other opinions as Agent may reasonably request, all in form and substance satisfactory to Agent; 

        (k)   Upon
Agent's request, Agent shall have received a copy of the Assignment of Representations and Warranties, duly executed by an authorized officer of Merger Newco and
acknowledged by selling stockholders of ADC 

        (l)    Agent
shall have received evidence that CT Corporation has been appointed as agent for service of process for Merger Newco; and 

        (m)  The
ADC Merger shall have been consummated on or prior to July 30, 2004. 

        6.    Consent to IV Diagnostics Purchase.    As of the Effective Date, Agent and Requisite Lenders hereby agree that
the consummation of the IV Diagnostics Purchase shall not create a breach under Sections 6.1 of the Credit Agreement,  provided that: 

        (a)   the
Credit Parties do not expend any cash in connection with the IV Diagnostics Purchase other than for costs and expenses and cash payments to Dror Yeffet or Mihal
Jacobi which do not exceed $10,000 in the aggregate; 

        (b)   Agent
shall have received (i) a Joinder Agreement pursuant to which IV Diagnostics agrees to become a party to the Credit Agreement for purposes of  Section 11.19 thereof; provided, that such action does not violate the "financial assistance"
laws of the United Kingdom or require "white wash procedures" thereunder, and (ii) such further assurances regarding the existing fixed and floating charge in favor of Agent over all of the
issued and outstanding equity interests of IV Diagnostics (the "IV Diagnostics Stock") as Agent shall reasonably request, including a pledge agreement
or pledge amendment (the "IV Diagnostics Pledge Agreement") in form and substance satisfactory to Agent, in either case duly executed and delivered by
an authorized officer of IV Diagnostics and/or Inverness UK, as applicable; 

6

 

        (c)   Agent
shall have received an original certificate representing the IV Diagnostics Stock pledged by Inverness UK pursuant to the terms of the IV Diagnostics Pledge
Agreement; 

        (d)   Agent
shall have received a copy of IV Diagnostics' (i) charter documents and all amendments thereto and (ii) good standing certificates or the foreign
equivalent and certificates of qualification to conduct business in each jurisdiction where its ownership or lease of property or the conduct of its business requires such qualification, each dated a
recent date and certified by the applicable authorized Governmental Authority; 

        (e)   Agent
shall have received updated Schedules 11.19(a) and 11.19(b) to the Credit Agreement, revised to include
Indebtedness and Liens of IV Diagnostics; 

        (f)    Agent
shall have received a copy of IV Diagnostics' (i) bylaws and all amendments thereto and (ii) resolutions of IV Diagnostics' Board of Directors and,
to the extent required under applicable law, stockholders, approving and authorizing the execution, delivery and performance of the Loan Documents to which IV Diagnostics is, or will be, a party and
the transactions to be consummated in connection therewith, each certified by an authorized officer of IV Diagnostics (after giving effect to the IV Diagnostics Purchase) as being in full force and
effect without any modification or amendment; 

        (g)   Agent
shall have received a copy of Inverness UK's (i) bylaws and all amendments thereto and (ii) resolutions of Inverness UK's Board of Directors and, to
the extent required under applicable law, stockholders, approving and authorizing the execution, delivery and performance of the purchase agreement with respect to the purchase of IV Diagnostics and
the Loan Documents to which Inverness UK is, or will be, a party and the transactions to be consummated in connection therewith, each certified by Inverness UK's corporate secretary or an assistant
secretary (after giving effect to the IV Diagnostics Purchase) as being in full force and effect without any modification or amendment; 

        (h)   Agent
shall have received a signature and incumbency certificate of the officers of IV Diagnostics, certified by IV Diagnostics' corporate secretary or an assistant
secretary (after giving effect to the IV Diagnostics Purchase) as being true, accurate, correct and complete in all respects; 

        (i)    Agent
shall have received executed copies of any stock purchase agreement executed in connection with the IV Diagnostics Purchase, together with all amendments thereto,
and all documentation delivered in connection therewith (each of which shall be in form and substance satisfactory to Agent), certified by an authorized signatory for Inverness UK to be true and
complete and in full force and effect as of the Effective Date; 

        (j)    Upon
Agent's request, Agent shall have received evidence that CT Corporation has been appointed as agent for service of process of IV Diagnostics; and 

        (k)   The
IV Diagnostics Purchase shall have been consummated on or prior to July 30, 2004. 

7

   
        7.    Amendment to Credit Agreement.    After the Effective Date, the Credit Agreement shall be amended as follows:

        (a)   Clause (i)
of Section 6.2 is hereby deleted in its entirety and replaced with the following: 

"(i) Scandinavian Micro Biodevices Aps shall be permitted to make and permit to exist an investment in [Lumiscence A/S], which investment shall
be limited solely to the contribution by Scandinavian Micro Biodevices Aps of its interest in and to that certain Danish patent application (#PA 2003-01764) in exchange for an equity
interest in the outstanding capital of [Lumiscence A/S]; provided, however, that if at any time,
[Lumiscence A/S] qualifies as a Subsidiary of Scandinavian Micro Biodevices Aps under the Credit Agreement, Scandinavian Micro Biodevices Aps shall cause Lumiscence A/S to
execute such documents as shall be reasonably requested by Agent to effect the joinder of [Lumiscence A/S] as a Credit Party to this Agreement; and (j) any Credit Party
may make capital contributions to any other Credit Party it holds an interest in and any Credit Party may make any other investments in any other Credit Parties to the extent permitted under
Section 6.5(b)."

        (b)   The
definition of "Excluded US Subsidiaries" in Annex A of the Credit Agreement shall be deleted in its entirety and
replaced with the following: 

"means, collectively, (a) IVC Industries, Inc., a Delaware corporation; and (b) SelfCare- PBM, LLC, a Delaware limited liability
company."

        (c)   The
definition of "Excluded European Subsidiaries" in Annex A of the Credit Agreement shall be deleted in its entirety
and replaced with the following: 

"means, collectively, (a) Unipath BV, an entity organized under the laws of The Netherlands; (b) Unipath Management Company Limited, a company organized under the
laws of England and Wales; (c) Unipath Scandinavia AB, an entity organized under the laws of Sweden; (d) Inverness Medical Benelux Bvab, an entity organized under the laws of Belgium;
(e) Hall Laboratories Ltd., an entity organized under the laws of Yukon, Canada; (f) Orgenics and each of the Subsidiaries of Orgenics; and (e) IV Diagnostics and each of
the Subsidiaries of IV Diagnostics."

        (d)   Annex
A of the Credit Agreement shall be amended to insert the following definition: 

""IV Diagnostics" means IV Diagnostics Limited, an entity organized under the laws of the United Kingdom."

        (e)   Section 11.9 of the Credit Agreement shall be deleted in its entirety and replaced with the following: 

"11.19 Negative Pledge.    Each of Orgentics, IV Diagnostics and Unipath Scandinavia AB hereby covenant and agree with Agent and Lenders
that such Person shall not (a) create, incur, assume or permit to exist any Indebtedness other than (i) such Indebtedness existing on the Closing Date or with respect to IV Diagnostics
on the date of the Sixth Amendment and Consent to this Agreement, listed on Disclosure Schedule 11.19(a), provided that the aggregate
combined amount of Indebtedness of Orgenics and IV Diagnostics does not exceed $1,000,000 (or the Equivalent Amount thereof) at any time, and (iii) refinancings thereof or amendments or
modifications thereto that do not have the effect of increasing the principal amount thereof or changing the amortization thereof (other than to extend the same) and that are otherwise on terms and
conditions no less favorable to such Person, as determined by Agent in good faith, than the terms of the Indebtedness being refinanced, amended or modified, or (b) create, incur, assume or
permit to exist any Lien on or with respect to any of its other properties or assets (whether now owned or hereafter acquired) except for (i) Permitted Encumbrances; (ii) Liens in
existence on the date hereof or with respect to IV Diagnostics on the date of the Sixth Amendment and Consent to this Agreement and summarized on Disclosure
Schedule 11.19(b) securing the Indebtedness described on Disclosure Schedule 11.19(a) and (iii) permitted refinancings, extension and
renewals thereof, including extensions or renewals of any such Liens; provided that the principal  

8

 

 amount of the Indebtedness so secured is not increased and the Lien does not attach to any other property."  

        8.    Amendment to the Post Closing Letter.    As of the Amendment Effective Date,
clause (iii) of paragraph 1 of the Post Closing Letter shall be amended by deleting the date "May 31, 2004" as it appears therein and inserting the date "June 30, 2004" in
lieu thereof. 

        9.    Representations and Warranties.    To induce Agent and Requisite Lenders to enter into this Amendment, the
Credit Parties hereby, jointly and severally, represent and warrant that: 

        (a)   The
execution, delivery and performance by Acquisition Newco, Investment Newco, Merger Newco and each Credit Party of the agreements executed or to be executed in
connection with the Viva and DMD Purchase, the ADC Merger, the U.C. Light Investment and the IV Diagnostics Purchase (collectively the "Transaction
Documents") and any Loan Documents to which it is or will be a party
and the creation of all Liens provided for therein: (i) are within such Person's corporate, company or partnership power; (ii) have been (or will be prior to execution thereof) duly
authorized by all necessary corporate, limited liability company or limited partnership action; (iii) do not contravene any provision of such Person's charter, bylaws or equivalent constitutive
documents or partnership or operating agreement, as applicable; (iv) do not violate any law or regulation, or any order or decree of any court or Governmental Authority; (v) do not
conflict with or result in the breach or termination of, constitute a default under or accelerate or permit the acceleration of any performance required by, any indenture, mortgage, deed of trust,
lease, agreement or other instrument to which such Person is a party or by which such Person or any of its property is bound; (vi) do not result in the creation or imposition of any Lien upon
any of the property of such Person; and (vii) do not require the consent or approval of any Governmental Authority or any other Person except those which will have been duly obtained, made or
complied with prior to the Effective Date. 

        (b)   This
Amendment has been duly executed and delivered by or on behalf of each of the Credit Parties. 

        (c)   This
Amendment constitutes a legal, valid and binding obligation of each of the Credit Parties, enforceable against each of them in accordance with its terms. 

        (d)   No
Default or Event of Default has occurred and is continuing after giving effect to this Amendment. 

        (e)   No
action, claim or proceeding is now pending or, to the knowledge of any Credit Party, threatened against such Credit Party, at law, in equity or otherwise, before any
court, board, commission, agency or instrumentality of any foreign, federal, state, or local government or of any agency or subdivision thereof, or before any arbitrator or panel of arbitrators, which
(i) challenges any Credit Party's right or power to enter into or perform any of its obligations under any Transaction Document, this Amendment or any other Loan Document to which it is or will
be, a party, or the validity or enforceability of this Amendment, any Transaction Document, the Credit Agreement or any Loan Document or any action taken thereunder, or (ii) has a reasonable
risk of being determined adversely to any Credit Party and that, if so determined, could reasonably be expected to have a Material Adverse Effect after giving effect to this Amendment. 

        (f)    The
representations and warranties of Acquisition Newco, Investment Newco, Merger Newco and the Credit Parties contained in the Transaction Documents, the Credit
Agreement and each other Loan Document shall be true and correct in all material respects on and as of (i) the Effective Date, (ii) the date the Viva and DMD Purchase is consummated
(both before and after giving effect to the Viva and DMD Purchase), (iii) the date the ADC Merger is consummated (both before and after giving effect to the ADC Merger), (iv) the date
the U.C. Light Investment is consummated (both before and after giving effect to the U.C. Light Investment), and (v) the 

9

 

date
the IV Diagnostics Purchase is consummated (both before and after giving effect to the IV Diagnostics Purchase; in each case, with the same effect as if such representations and warranties had
been made on and as of such date, except that any such representation or warranty which is expressly made only as of a specified date need be true only as of such date. 

        (g)   Prior
to the consummation of the Proposed Transactions, the Reporting Credit Parties shall have completed their due diligence investigation with respect to such
transactions, which investigation shall have been conducted in a similar manner to that which would have been conducted by a prudent purchaser of a comparable business. 

        (h)   Each
Credit Party that is a party to the Transaction Documents or any Loan Documents delivered in connection with the Proposed Transactions (after taking into
consideration all rights of contribution and indemnity such Credit Party has against Innovations and each other Subsidiary of Innovations) will be Solvent upon consummation of the Proposed
Transactions. 

        (i)    No
information contained in the Transaction Documents or any document furnished in connection with any of the foregoing (including, without limitation, the memorandums
describing the proposed transactions) contains or will contain any untrue statement of a material fact or omits or will omit to state a material fact necessary to make the statements contained therein
not misleading in light of the circumstances under which they were made. 

        (j)    The
value of the SMB's interest in the patent being transferred by SMB to Investment Newco is not greater than $250,000 and such patent is not material to any Credit
Party's business. 

        (k)   As
of May 31, 2004, the Credit Parties have substantially complied with the provisions of clause (iii) of paragraph 1 of the Post Closing Letter. 

        10.    No Other Amendments/Waivers.    Except as expressly provided herein, (a) the Credit Agreement shall be
unmodified and shall continue to be in full force and effect in accordance with its terms and (b) this Amendment shall not be deemed a waiver of any term or condition of any Loan Document and
shall
not be deemed to prejudice any right or rights which Agent or any Lender may now have or may have in the future under or in connection with any Loan Document or any of the instruments or agreements
referred to therein, as the same may be amended from time to time. 

        11.    Outstanding Indebtedness; Waiver of Claims.    Each of Borrowers and other Credit Parties hereby acknowledges
and agrees that as of May 18, 2004, (a) there are no outstanding European Revolving Loans and (b) there are no outstanding US Revolving Loans. Borrowers and each other Credit
Party hereby waives, releases, remises and forever discharges Agent, Lenders and each other Indemnified Person from any and all claims, suits, actions, investigations, proceedings or demands arising
out of or in connection with the Credit Agreement (collectively, "Claims"), whether based in contract, tort, implied or express warranty, strict
liability, criminal or civil statute or common law of any kind or character, known or unknown, which any Borrower or any other Credit Party ever had, now has or might hereafter have against Agent or
Lenders which relates, directly or indirectly, to any acts or omissions of Agent, Lenders or any other Indemnified Person on or prior to the Effective Date,  provided, that no Borrower nor any other
Credit Party waives any Claim solely to the extent such Claim relates to Agent's or any Lender's gross
negligence or willful misconduct. 

        12.    Expenses.    Borrowers hereby reconfirm their obligations pursuant to  Section 11.3 of the Credit Agreement to pay and
reimburse Agent for all reasonable costs and expenses (including, without limitation, reasonable
fees of counsel) incurred in connection with the negotiation, preparation, execution and delivery of this Amendment and all other documents and instruments delivered in connection herewith. 

10

 

        13.    Effectiveness.    This Amendment shall become effective as of the date hereof (the
"Effective Date") only upon satisfaction in full in the judgment of Agent of each of the following conditions: 

        (a)    Amendment.    Agent shall have received six (6) original signature pages to this Amendment, duly
executed and delivered by Agent, Requisite Lenders and each of the Credit Parties. 

        (b)    Payment of Expenses.    Borrowers shall have paid to Agent all costs, fees and expenses owing in connection
with this Amendment and the other Loan Documents and due to Agent (including, without limitation, reasonable legal fees and expenses). 

        (c)    Representations and Warranties.    The representations and warranties of or on behalf of each of the Credit
Parties in this Amendment shall be true and correct on and as of the Effective Date; provided, however that the amendment under  Section 7(e) above
shall not be effective at any time if the
agreement by IV Diagnostics thereof would violate the "financial assistance" laws of the United Kingdom or require "white wash procedures" thereunder. 

        14.    GOVERNING LAW.    THIS AMENDMENT SHALL BE GOVERNED BY, AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE
OF NEW YORK. 

        15.    Counterparts.    This Amendment may be executed by the parties hereto on any number of separate counterparts
and all of said counterparts taken together shall be deemed to constitute one and the same instrument. 

        16.    Consent to Amendment to Schedules to Credit Agreement.    Each of the Requisite Lenders hereby consents to the
amendments to the Schedules to the Credit Agreement referred to in Section 2(e) of this Amendment. 

        IN
WITNESS WHEREOF, this Amendment has been duly executed as of the date first written above. 

	 	 	BORROWERS
	

 	
 	

WAMPOLE LABORATORIES, LLC.

INVERNESS MEDICAL (UK) HOLDINGS LIMITED
	

 	
 	

By:	

/s/  ANTHONY J. BERNARDO      
 Name:  Anthony J. Bernardo

Title:    Duly Authorized Signatory
	

 	
 	
AGENT AND LENDERS
	

 	
 	

GENERAL ELECTRIC CAPITAL CORPORATION,

as Agent and Lender
	

 	
 	

By:	

/s/  ILLEGIBLE      
 Duly Authorized Signatory
	

 	
 	

MERRILL LYNCH CAPITAL, a division of Merrill Lynch Business Financial Services Inc., as Co-Syndication Agent, Documentation Agent and Lender
	 	 	 	 

11

 

	

 	
 	

By:	

 Duly Authorized Signatory
	

 	
 	

UBS SECURITIES LLC,

as Co-Syndication Agent
	

 	
 	

By:	

/s/  DAVID A. JUGE, MANAGING DIRECTOR      
 Duly Authorized Signatory
	

 	
 	

By:	

/s/  OLIVER O TRUMBO, II, DIRECTOR      
 Duly Authorized Signatory
	

 	
 	

UBS AG, CAYMAN ISLANDS BRANCH,

as a Lender
	

 	
 	

By:	

/s/  WILFRED V. SAINT, DIRECTOR BANKING PRODUCTS SERVICES, US      
 Duly Authorized Signatory
	

 	
 	

By:	

/s/  JOSELIN FERNANDES, ASSOCIATE DIRECTOR BANKING PRODUCTS SERVICES, US      
 Duly Authorized Signatory

12

 

        The following Persons are signatories to this Amendment in their capacity as Credit Parties and not as Borrowers. 

	 	 	INVERNESS MEDICAL INNOVATIONS, INC.

INVERNESS MEDICAL, INC.

UNIPATH DIAGNOSTICS, INC.

UNIPATH ONLINE, INC.

OSTEX INTERNATIONAL, INC.

INVERNESS MEDICAL INTERNATIONAL HOLDING CORP.

INVERNESS MEDICAL INTERNATIONAL HOLDING CORP. II

UNIPATH LIMITED APPLIED BIOTECH, INC.

FOREFRONT DIAGNOSTICS, INC.

MORPHEUS ACQUISITION CORP.

MORPHEUS ACQUISITION LLC

INVERNESS MEDICAL CANADA INC.

MEDICALE INVERNESS CANADA INC.

INNOVATIONS RESEARCH LLC
	

 	
 	

By:	

/s/  ANTHONY J. BERNARDO      
 Name:  Anthony J. Bernardo

Title:    Duly Authorized Signatory
	

 	
 	

ORGENICS INTERNATIONAL HOLDINGS BV

INVERNESS MEDICAL SWITZERLAND LTD

LIAB. CO

UNIPATH DIAGNOSTICS GMBH

CAMBRIDGE DIAGNOSTICS IRELAND LIMITED

PREGYMED GMBH

SCANDINAVIAN MICRO BIODEVICES APS

SELFCARE TECHNOLOGY, INC.
	

 	
 	

By:	

/s/  PAUL T. HEMPEL      
 Name:  Paul T. Hempel

Title:    Duly Authorized Signatory

	 MORPHEUS ACQUISITION LLC	 	 	 

13

QuickLinks

EXHIBIT 10.1QuickLinks
 -- Click here to rapidly navigate through this document

 
 

EXHIBIT 10.2    
    

SEVENTH AMENDMENT AND CONSENT TO SECOND AMENDED

AND RESTATED CREDIT AGREEMENT  

        THIS SEVENTH AMENDMENT AND CONSENT TO SECOND AMENDED AND RESTATED CREDIT AGREEMENT, dated as of July 27, 2004 (this
"Amendment"), to the Second Amended and Restated Credit Agreement, dated as of September 30, 2003 (as amended, supplemented or otherwise modified
from time to time, the "Credit Agreement"), by and among General Electric Capital Corporation, as Agent and Lender
("Agent"), Inverness Medical Innovations, Inc. ("Innovations"), Wampole Laboratories, Inc.
and Inverness Medical (UK) Holdings Limited, as borrowers ("Borrowers"), the other Credit Parties signatory thereto, Merrill Lynch Capital, a division
of Merrill Lynch Business Financial Services Inc., as documentation agent, co-syndication agent and lender, UBS Securities LLC, as co-syndication agent, and the lenders
signatory thereto from time to time (collectively, the "Lenders"). 

WITNESSETH  

        WHEREAS, Borrowers have notified Agent that Borrowers, IVC Industries, Inc., a Delaware corporation
("IVC"), and Hall Laboratories Ltd., an entity organized under the laws of Yukon, Canada ("Hall")
desire that (i) IVC become a US Credit Party to the Credit Agreement and to cease being an Excluded US Subsidiary, and (ii) Hall become a European Credit Party to the Credit Agreement
and to cease being an Excluded European Subsidiary; 

        WHEREAS,
IVC is party to a Trust Indenture by and among New Jersey Economic Development Authority and First Fidelity Bank, National Association, New Jersey, Trustee (the
"Bond Trustee") relating to $5,600,000 in aggregate original principal amount of New Jersey Economic Development (Composite Issue) 1991 Series F
Bonds (the "Bonds"), as well as certain related loan and reimbursement agreements which prohibit IVC from incurring additional indebtedness or
refinancing existing indebtedness; 

        WHEREAS,
Borrowers and IVC desire to either defease or redeem all the outstanding Bonds in accordance with the terms and conditions of the Bonds, thereby extinguishing the restrictive
covenants regarding indebtedness relating thereto (collectively, the "Bond Satisfaction"); 

        WHEREAS,
Borrowers have publicly disclosed that they intend to establish manufacturing and distribution operations in China during the third quarter of 2004 in order to significantly
reduce costs (the "China Operations"), and accordingly Inverness Medical, Inc. has recently entered into a Processing Trade Agreement with a
Chinese manufacturer, Shanghai Hua Guan Biochip Co., Ltd (the "Trade Agreement"), the first of potentially several Chinese partners; and 

        WHEREAS,
Borrowers have determined that for tax purposes it will be beneficial to form a private limited company in the Republic of Ireland ("Trade
Newco") for the purpose of conducting the China Operations; 

        WHEREAS,
Agent and Requisite Lenders or all Lenders, as applicable, have agreed to amend the Credit Agreement in the manner, and on the terms and conditions, provided for herein; and 

        WHEREAS,
Agent and Requisite Lenders have agreed to extend the time period for compliance with certain covenants set forth in the Sixth Amendment and Consent to the Credit Agreement (the
"Sixth Amendment"), in the manner, and on the terms and conditions, provided for herein. 

        NOW
THEREFORE, in consideration of the premises and for other good and valuable consideration, the receipt, adequacy and sufficiency of which are hereby acknowledged, the parties hereto
agree as follows: 

        1.    Definitions.    Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the
Credit Agreement. 

 

        2.    Amendment to Credit Agreement as of the Effective Date.    As of the Effective Date, the Credit Agreement shall
be amended as follows: 

        (a)   The
charts set forth under the second paragraph of clause (a) of Section 1.5 are hereby deleted in their
entirety and replaced with the following: 

	If Total Leverage Ratio is:
 
	 	Level of Applicable Margins:
 

	< 2.25	 	Level I
	< 2.75, but > 2.25	 	Level II
	< 4.00, but > 2.75	 	Level III
	> 4.00	 	Level IV

	 
	 	Applicable Margins
	 
	 
	 	Level I
	 	Level II
	 	Level III
	 	Level IV
	 
	Applicable US Revolver Index Margin	 	1.50	%	1.75	%	2.00	%	2.50	%
	Applicable US Revolver LIBOR Margin	 	2.75	%	3.00	%	3.25	%	3.75	%
	Applicable European Revolver Index Margin	 	1.50	%	1.75	%	2.00	%	2.50	%
	Applicable European Revolver LIBOR Margin	 	2.75	%	3.00	%	3.25	%	3.75	%
	Applicable US Term A Loan Index Margin	 	2.00	%	2.50	%	2.75	%	N/A	 
	Applicable US Term A Loan LIBOR Margin	 	3.25	%	3.75	%	4.00	%	N/A	 
	Applicable US Term B Loan Index Margin	 	2.50	%	3.00	%	3.25	%	N/A	 
	Applicable US Term B Loan LIBOR Margin	 	3.75	%	4.25	%	4.50	%	N/A	 
	Applicable European Term Loan Index Margin	 	2.00	%	2.50	%	2.75	%	N/A	 
	Applicable European Term Loan LIBOR Margin	 	3.25	%	3.75	%	4.00	%	N/A	 
	Applicable L/C Margin	 	2.75	%	3.00	%	3.25	%	3.75	%

        The
Applicable Margins will be at Level IV as of June 30, 2004 (it being understood that as of such date the Term Loans have been repaid and the Term Loan Commitment of each
Lender has terminated). 

        Commencing
with the first day of the first calendar month that occurs more than 5 days after delivery of Borrowers' quarterly Financial Statements to Lenders for the Fiscal
Quarter ending June 30, 2004, the Applicable L/C Margin, the Applicable US Revolver Index Margin, the Applicable US Revolver LIBOR Margin, the Applicable European Revolver Index Margin, the
Applicable European Revolver LIBOR Margin, the Applicable European Term Loan Index Margin, the Applicable European Term Loan LIBOR Margin, the Applicable US Term A Loan Index Margin and the Applicable
US Term A Loan LIBOR Margin shall be adjusted (up or down) prospectively on a quarterly basis as determined by Borrowers' consolidated financial performance. 

        (b)   Clause (b)
of Section 6.1 is hereby deleted in its entirety and replaced with the following: 

"(b)
except for (i) the formation of any Subsidiary or any acquisition of all of the Stock of any Person (an "Acquisition Subsidiary") solely for
the purpose of consummating a Permitted Acquisition and provided that prior to the consummation of any Permitted Acquisition such Acquisition Subsidiary (A) shall constitute an Excluded US
Subsidiary or Excluded European Subsidiary, as applicable, (and, after consummation of such Permitted Acquisition, shall constitute a US Credit Party or European Credit Party, as applicable)
(B) shall hold no assets (other than the greater of $10,000 and any minimum capital required by law), (C) shall not conduct any business and (D) no Credit Party shall transfer any
funds or other assets to, such Acquisition Subsidiary other than capital contributions permitted under the foregoing clause (B) and as necessary to consummate the Permitted Acquisition, and
(ii) the formation of Morpheus Acquisition Corp. and Morpheus Acquisition LLC and the acquisition of assets in connection with the Acquisition, form 

2

 

any
Subsidiary or acquire all or substantially all of the assets or Stock of any Person without the prior written consent of Requisite Lenders." 

        (c)   The
second clause (i) of Section 6.1 is hereby deleted in its entirety and replaced with the following: 

"(i) Agent
shall receive at least 10 Business Days' prior written notice of such proposed Permitted Acquisition, which notice shall include a reasonably detailed description of such proposed
Permitted Acquisition (Agent hereby agreeing to provide copies of such notice to the Lenders promptly following receipt thereof);" 

        (d)   Clause (B)
of Section 6.1(v) is hereby deleted in its entirety and replaced with the following: 

"(B)
cash not to exceed $5,000,000 in the aggregate for any Permitted Acquisition and not to exceed $15,000,000 in the aggregate for all Permitted Acquisitions in any Fiscal Year." 

        (e)   Clause (viii)
of Section 6.1 is hereby deleted in its entirety and replaced with the following: 

"(viii)
at or prior to the closing of any Permitted Acquisition, Agent will be granted a first priority perfected Lien (subject to Permitted Encumbrances) in all assets acquired pursuant thereto or in
the assets and Stock of the Target and any Acquisition Subsidiary, and each Credit Party, any Acquisition Subsidiary and the Target shall have executed such documents and taken such actions as may be
required by Agent in connection therewith; provided, however, that, the Agent may, in its sole
discretion, elect to waive such condition with respect to all or a portion of the assets of the Target or any Acquisition Subsidiary to the extent that (A) any such Target or Acquisition
Subsidiary is formed outside of the United States and (B)(1) the grant of such first priority perfected Lien, the execution of any such documents or the performance of any such actions is prohibited
by the law of the jurisdiction of formation of the applicable Credit Party, any Acquisition Subsidiary or the Target, (2) the Agent determines that, taking into consideration the costs
associated therewith in relation to the value or importance of such first priority perfected Lien, it is not in the best interest of both the Lenders and the Credit Parties to grant such Lien, or
(3) the value of the assets or Stock with respect to any Permitted Acquisition which shall be the subject of any waiver under this  Section 6.1(viii) is, in the aggregate, less than $3,000,000;
provided,  further, that Agent may, at any time and from time to time elect, in its sole discretion, to enforce the conditions that had been previously
waived
under this Section 6.1(viii)." 

        (f)    Clause (1)
of Section 6.1(ix) is hereby deleted in its entirety and replaced with the following: 

"(1)
a pro forma consolidated balance sheet, income statement and cash flow statement of the Reporting Credit Parties (the "Acquisition Pro Forma"),
based on recent financial statements, which shall be complete and shall fairly present in all material respects the assets, liabilities, financial condition and results of operations of Innovations
and its Subsidiaries in accordance with GAAP consistently applied, but taking into account such Permitted Acquisition and the funding of all Loans in connection therewith, and such Acquisition Pro
Forma shall reflect that on a pro forma basis, (A) no Event of Default has occurred and is continuing or would result after giving effect to such Permitted Acquisition, (B) US Borrower
and European Borrower shall have aggregate US Revolving Borrowing Availability and European Revolving Borrowing Availability of at least $20 million, US Borrower shall have US Revolving
Borrowing Availability of at least $7 million and European Borrower shall have European Revolving Borrowing Availability of at least $7 million, in each case, both before and after
giving effect to such Permitted Acquisition and (C) the Reporting Credit Parties would have been in compliance with the financial covenants set forth in Annex
F for the four quarter period reflected in the Compliance Certificate most recently 

3

 

delivered
to Agent pursuant to Annex E prior to the consummation of such Permitted Acquisition (after giving effect to such Permitted Acquisition and
all Loans funded in connection therewith as if made on the first day of such period);" 

        (g)   The
first sentence of Section 6.18 is hereby deleted in its entirety and replaced with the following: 

"No
Credit Party shall enter into any operating lease for Equipment or Real Estate, if the aggregate of all operating lease payments payable in any year for all Credit Parties on a consolidated basis
would exceed $9,500,000 (or the Equivalent Amount thereof)." 

        (h)   The
following definitions shall be added to Annex A of the Credit Agreement and inserted in alphabetical order therein: 

"Acquisition Subsidiary" has the meaning ascribed to it in Section 6.1(b). 

"European Revolving Borrowing Availability" means as of any date of determination the European Maximum Amount  less the sum of the aggregate European Revolving Loan and
European Swing Line Loan then outstanding. 

"IVC and Hall Joinder Date" means the date on which the Agent is satisfied that all of the conditions set forth in Paragraph 10(b) of the Seventh
Amendment to the Credit Agreement have been satisfied in full." 

"US Revolving Borrowing Availability" means as of any date of determination the US Maximum Amount less the sum of the aggregate US Revolving Loan and US
Swing Line Loan then outstanding. 

        (i)    The
definition of "EBITDA" in Annex A of the Credit Agreement is hereby deleted in its entirety and replaced with the
following: 

"EBITDA" means, with respect to any Person for any fiscal period, without duplication, an amount equal to (a) consolidated net income of such
Person for such period determined in accordance with GAAP, minus (b) the sum of (i) income tax credits, (ii) interest income,
(iii) gain from extraordinary items for such period, (iv) any aggregate net gain (but not any aggregate net loss) during such period arising from the sale, exchange or other disposition
of capital assets by such Person (including any fixed assets, whether tangible or intangible, all inventory sold in conjunction with the disposition of fixed assets and all securities), and
(v) any other non-cash gains that have been added in determining consolidated net income, in each case to the extent included in the calculation of consolidated net income of such
Person for such period in accordance with GAAP, but without duplication, plus (c) the sum of (i) any provision for income taxes,
(ii) Interest Expense, (iii) loss from extraordinary items for such period, including all costs incurred in connection with a proposed Subordinated Bond Issuance which is not successful,
(iv) the amount of non-cash charges (including depreciation and amortization) for such period to the extent that a cash outlay is not reasonably foreseeable, (v) amortized
debt discount for such period, (vi) the amount of any deduction to consolidated net income as the result of any grant to any members of the management of such Person of any Stock, in each case
to the extent included in the calculation of consolidated net income of such Person for such period in accordance with GAAP, but without duplication and (vii) without duplication of any amount
included in clause (c)(iv) above and with respect to the Fiscal Quarter ending June 30, 2004, $1,393,063.97, representing the write-off in such Fiscal Quarter of
certain accounts receivable owed by Scienta (f/k/a Drug Free Enterprises) to certain of the Credit Parties. For purposes of this definition, the following items shall be excluded in determining
consolidated net income of a Person: (1) the income (or deficit) of any other Person accrued prior to the date it became a Subsidiary of, or was merged or consolidated into, such Person or any
of such Person's Subsidiaries; (2) the income (or deficit) of any other Person 

4

 

(other
than a Subsidiary) in which such Person has an ownership interest, except to the extent any such income has actually been received by such Person in the form of cash dividends or distributions;
(3) the undistributed earnings of any Subsidiary of such Person to the extent that the declaration or payment of dividends or similar distributions by such Subsidiary is not at the time
permitted by the terms of any contractual obligation or requirement of law applicable to such Subsidiary; (4) any restoration to income of any contingency reserve, except to the extent that
provision for such reserve was made in the ordinary course of business in accordance with GAAP within such Financial Covenant testing period; (5) any write-up of any asset;
(6) any net gain from the collection of the proceeds of life insurance policies; (7) any net gain or loss arising from the acquisition of any securities, or the extinguishment, under
GAAP, of any Indebtedness, of such Person, (8) in the case of a successor to such Person by consolidation or merger or as a transferee of its assets, any earnings of such successor prior to
such consolidation, merger or transfer of assets, and (9) any deferred credit representing the excess of equity in any Subsidiary of such Person at the date of acquisition of such Subsidiary
over the cost to such Person of the investment in such Subsidiary. 

        (j)    Annex
F of the Credit Agreement is amended and restated in its entirety with Annex F attached hereto. 

        3.    Sixth Amendment Covenants.    The Parties hereby covenant and agree to satisfy the covenants set forth in  Sections 3(a)(ii),
(b), (c),
(d), (e), (l) and  (n) of the Sixth Amendment on or before
August 20, 2004. Any failure to satisfy any such any such covenant on or before August 20, 2004
shall constitute an immediate Event of Default. 

        4.    Amendments to Credit Agreement as of the IVC and Hall Joinder Date.    As of the IVC and Hall Joinder Date, the
Credit Agreement shall be amended as follows: 

        (a)   Clause (iv)
of Section 6.3(a) is hereby deleted in its entirety and replaced with the following: 

"(iv)(A)
existing Indebtedness described in Disclosure Schedule (6.3) and refinancings thereof or amendments or modifications thereto that do not have
the effect of increasing the principal amount thereof or changing the amortization thereof (other than to extend the same), and that are otherwise on terms and conditions no less favorable to any
Credit Party, Agent or any Lender, as determined by Agent in good faith, than the terms of the Indebtedness being refinanced, amended or modified, and (B) Indebtedness secured solely by a Lien
on the IVC Mortgaged Property in an outstanding principal amount not exceeding the lesser of (x) $6,000,000 and (y) the fair market value of the IVC Mortgaged Property at the time of the
incurrence of such Indebtedness, as determined by a nationally recognized independent real property appraisal firm;" 

        (b)   Clause (b)
of Section 6.7 is hereby deleted in its entirety and replaced with the following: 

"(b)
Liens (A) in existence on the date hereof and summarized on Disclosure Schedule (6.7) securing Indebtedness described on  Disclosure Schedule (6.3),
and permitted refinancings, extensions and renewals thereof, including extensions or renewals of any such Liens;  provided that the principal amount of the Indebtedness so secured is not increased and
the Lien does not attach to any other property, and (B) on
the IVC Mortgaged Property which secures Indebtedness permitted under clause (iv)(B) of Section 6.3; 

        (c)   Section 11.19 is hereby deleted in its entirety and replaced with the following: 

"11.19
Negative Pledge.    Each of Orgenics and Unipath Scandinavia AB hereby covenant and agree with Agent and Lenders that such Person shall
not (a) create, incur, assume or permit to exist any Indebtedness other than (i) such Indebtedness existing on the Closing Date listed on Disclosure
Schedule 11.19(a), provided that the aggregate combined amount of Indebtedness of 

5

 

Orgenics
does not exceed $1,000,000 (or the Equivalent Amount thereof) at any time, and (ii) refinancings thereof or amendments or modifications thereto that do not have the effect of
increasing the principal amount thereof or changing the amortization thereof (other than to extend the same) and that are otherwise on terms and conditions no less favorable to such Person, as
determined by Agent in good faith, than the terms of the Indebtedness being refinanced, amended or modified, or (b) create, incur, assume or permit to exist any Lien on or with respect to any
of its other properties or assets (whether now owned or hereafter acquired) except for (i) Permitted Encumbrances; (ii) Liens in existence on the date hereof and summarized on  Disclosure Schedule 11.19(b)
 securing the Indebtedness described on Disclosure
Schedule 11.19(a) and (iii) permitted refinancings, extension and renewals thereof, including extensions or renewals of any such Liens;  provided that the principal
amount of the Indebtedness so secured is not increased and the Lien does not attach to any other property." 

        (d)   The
definition of "Excluded European Subsidiaries" in Annex A of the Credit Agreement is hereby deleted in its entirety
and replaced with the following: 

"Excluded European Subsidiary" means collectively, (a) Unipath BV, an entity organized under the laws of The Netherlands; (b) Unipath
Management Company Limited, a company organized under the laws of England and Wales; (c) Unipath Scandinavia AB, an entity organized under the laws of Sweden; (d) Inverness Medical
Benelux Bvab, an entity organized under the laws of Belgium; and (e) Orgenics and each of the Subsidiaries of Orgenics." 

        (e)   The
definition of "Excluded US Subsidiaries" in Annex A of the Credit Agreement is hereby deleted in its entirety and
replaced with the following: 

"Excluded US Subsidiary" means SelfCare- PBM, LLC, a Delaware limited liability company." 

        (f)    The
definition of "Reporting Credit Parties" in Annex A of the Credit Agreement is hereby amended by deleting "(other
than IVC Industries, Inc. and its Subsidiaries)" in the second line thereof. 

        (g)   The
following definition shall be added to Annex A of the Credit Agreement and inserted in alphabetical order therein: 

"IVC Mortgaged Property" means the real property owned by IVC Industries, Inc. and located at 500 Halls Mill Road, Freehold, New Jersey. 

        5.    Consent to Bond Satisfaction.    Agent and Requisite Lenders agree that the transfer of funds or other assets
from any Credit Party to or for the benefit of IVC, the proceeds of which are used solely to consummate the Bond Satisfaction, shall not create a breach under Sections
6.2 or 6.14 of the Credit Agreement (the "Consent");  provided, that the aggregate amount of all funds or assets so transferred, then paid to IVC or the Bond
Trustee for the purpose of defeasing or redeeming the Bonds in accordance with the Bond Satisfaction by any Credit Party shall not exceed $1,500,000; and  provided, further, that upon the transfer of such funds, IVC shall execute a promissory note in favor of
the Credit Party transferring such funds and such Credit Party shall pledge such note to Agent. 

6

   
        6.    Consent to Formation and Operation of Trade Newco.    Agent and Requisite Lenders agree that the formation of
Trade Newco, the assignment of the Trade Agreement to Trade Newco and the commencement of operations by Trade Newco, including the transfer of funds or assets from any European Credit Party to Trade
Newco and the importation, exportation and sale of goods shall not create a breach under Sections 6.1(b),  6.2, 6.3, or 6.8 of the Credit Agreement (the
"Consent"); provided, that (a) at all times,
notwithstanding the provisions of Section 6.1(a)(iv) of the Credit Agreement, Swissco shall own and control all of the economic and voting rights
associated with all of the outstanding capital Stock of Trade Newco, (b) Trade Newco constitutes a European Credit Party, (c) notwithstanding the provisions of  Sections 6.2, 6.3(a) and 6.8(e) of the Credit Agreement,
the aggregate amount of all funds or assets paid or transferred to Trade Newco shall not exceed $1,500,000, (d) upon the transfer of such funds, Trade Newco shall execute a promissory note in
favor of the Credit Party transferring such funds and such Credit Party shall pledge such note to Agent and (e) each of the following conditions is satisfied on or prior to September 30,
2004; and provided, further, that the failure to comply with such provisions within such timeframe (or any of the provisions in the foregoing clauses (a) through (d)) shall constitute an
immediate Event of Default: 

        (i)    Joinder.    Agent shall have received a joinder agreement, in form and substance satisfactory to Agent, duly
executed by Trade Newco pursuant to which, inter alia, Trade Newco joins the Credit Agreement and the other Loan Documents as a European Credit Party. 

        (ii)    Security Interest and Code Filings.    

        (A)  Trade
Newco shall have granted a valid first priority perfected security interest (subject to Permitted Encumbrances) in all of its assets to secure the Obligations of
the European Credit Parties and execute all documents (including financing statements under the Code (or foreign equivalent) and other applicable documents under the laws of any jurisdiction with
respect to the perfection of Liens in form and substance reasonably acceptable to Agent) as Agent may request in order to perfect its security interest in such assets. 

        (B)  Trade
Newco shall provide copies of Code (or the foreign equivalent thereof) search reports listing all effective financing statements (or equivalent information) that
name Trade Newco as debtor, together with copies of such financing statements (or equivalent information), none of which shall cover the assets of Trade Newco. 

        (iii)    Pledge Amendment.    Agent shall have received a pledge amendment, in form and substance satisfactory to
Agent, pursuant to which (i) Swissco pledges one hundred percent (100%) of the issued
and outstanding Stock of Trade Newco (the "Trade Newco Stock") to Agent, duly executed by an authorized officer of Swissco. Agent shall have received
original certificates representing the Trade Newco Stock pledged by Swissco. 

        (iv)    Cash Management.    Agent shall have received tri-party blocked account agreements, in form and
substance reasonably satisfactory to Agent, duly executed and delivered by Trade Newco and each bank where Trade Newco has established a deposit or disbursement account (other than payroll accounts),
in accordance with the requirements set forth in Section 1.8 and Annex C of the Credit Agreement. 

        (v)    Schedules.    Agent shall have received (x) updated Schedules 3.1, 3.2, 3.6, 3.8
and 3.19 to the Credit Agreement and (y) a revised Exhibit A-1 updated to include Material Contracts, if any, to which Trade Newco is a party, each in
form and substance satisfactory to Agent. 

        (vi)    Organizational Documents and Good Standing.    Agent shall have received a copy of each of Trade Newco's
(i) organizational documents and all amendments thereto and (ii) good standing certificates or the foreign equivalent and certificates of qualification to conduct business in each
jurisdiction where their respective ownership or lease of property or the conduct of its business 

7

 

requires
such qualification, each dated a recent date and certified by the applicable authorized Governmental Authority. 

        (vii)    Bylaws and Resolutions.    Agent shall have received a copy of (i) Trade Newco's bylaws (or foreign
equivalent thereof) and all amendments thereto, and (ii) resolutions of Trade Newco's board of directors approving and authorizing the execution, delivery and performance of the Loan Documents
to which Trade Newco is, or will be a party and the transactions to be consummated in connection therewith, each certified by an authorized officer of Trade Newco as being in full force and effect
without any modification or amendment. 

        (viii)    Incumbency.    Agent shall have received a signature and incumbency certificate of the officers of Trade
Newco, certified by Trade Newco's, as applicable, corporate secretary or an assistant secretary as being true, accurate, correct and complete in all respects. 

        (ix)    Opinion of Counsel.    Agent shall have received legal opinions of counsel acceptable to Agent, including,
without limitation, Irish counsel (subject to customary qualifications) which shall provide that the Loan Documents have been duly authorized, executed and delivered by, and are enforceable against
Trade Newco and containing such other opinions as Agent may reasonably request, all in form and substance satisfactory to Agent. 

        (x)    Appointment of Agent for Service of Process.    Agent shall have received evidence that CT Corporation has been
appointed as agent for service of process for Trade Newco. 

        7.    Representations and Warranties.    To induce Agent and Requisite Lenders or all Lenders, as applicable, to enter
into this Amendment, the Credit Parties hereby, jointly and severally, represent and warrant that: 

        (a)   The
execution, delivery and performance by each Credit Party of this Amendment and the performance of the Credit Agreement as amended by this Amendment (the
"Amended Credit Agreement") and the execution, delivery and performance by IVC and Hall of any other Loan Documents to which it is or will be a party
and the creation of all Liens provided for therein: (i) are within such Person's corporate, company or partnership power; (ii) have been (or will be prior to execution thereof) duly
authorized by all necessary corporate, limited liability company or limited partnership action; (iii) do not contravene any provision of such Person's charter, bylaws or equivalent constitutive
documents or partnership or operating agreement, as applicable; (iv) do not violate any law or regulation, or any order or decree of any court or Governmental Authority; (v) do not
conflict with or result in the breach or termination of, constitute a default under or accelerate or permit the acceleration of any performance required by, any indenture, mortgage, deed of trust,
lease, agreement or other instrument to which such Person is a party or by which such Person or any of its property is bound; (vi) do not result in the creation or imposition of any Lien upon
any of the property of such Person, other than a Lien in favor of Agent; and (vii) do not require the consent or approval of any Governmental Authority or any other Person except those which
will have been duly obtained, made or complied with prior to the Effective Date. 

        (b)   This
Amendment has been duly executed and delivered by or on behalf of each of the Credit Parties. 

        (c)   This
Amendment constitutes a legal, valid and binding obligation of each of the Credit Parties, enforceable against each of them in accordance with its terms. 

        (d)   No
Default or Event of Default has occurred and is continuing after giving effect to this Amendment. 

        (e)   No
action, claim or proceeding is now pending or, to the knowledge of any Credit Party, threatened against such Credit Party, at law, in equity or otherwise, before any
court, board, commission, agency or instrumentality of any foreign, federal, state, or local government or of any 

8

 

agency
or subdivision thereof, or before any arbitrator or panel of arbitrators, which (i) challenges any Credit Party's right or power to enter into or perform any of its obligations under
this Amendment or any other Loan Document to which it is or will be, a party, or the validity or enforceability of this Amendment, the Credit Agreement or any Loan Document or any action taken
thereunder, or (ii) has a reasonable risk of being determined adversely to any Credit Party and that, if so determined, could reasonably be expected to have a Material Adverse Effect after
giving effect to this Amendment. 

        (f)    The
representations and warranties of the Credit Parties contained in the Amended Credit Agreement and each other Loan Document shall, after giving effect hereto) be
true and correct on and as of (i) the date hereof, and (ii) the Effective Date, in each case, with the same effect as if such representations and warranties had been made on and as of
such date, except that any such representation or warranty which is expressly made only as of a specified date need be true only as of such date. 

        (g)   Set
forth on Schedule 5(g) hereto is a true, correct and complete (in all material respects) list by facility of
the annual rental payments required under each Real Estate lease to which any Credit Party is a party on the date hereof and of each operating lease for Equipment, the aggregate annual payments of
which exceed $1,000,000, to which any Credit Party is a party on the date hereof. 

        8.    No Other Amendments/Waivers.    Except as expressly provided herein, (a) the Credit Agreement shall be
unmodified and shall continue to be in full force and effect in accordance with its terms and (b) this Amendment shall not be deemed a waiver of any term or condition of any Loan Document and
shall not be deemed to prejudice any right or rights which Agent or any Lender may now have or may have in the future under or in connection with any Loan Document or any of the instruments or
agreements referred to therein, as the same may be amended from time to time. 

        9.    Outstanding Indebtedness; Waiver of Claims.    Each of Borrowers and other Credit Parties hereby acknowledges
and agrees that as of July 27, 2004, (a) there are no outstanding European Revolving Loans and (b) there are no outstanding US Revolving Loans. Borrowers and each other Credit
Party hereby waives, releases, remises and forever discharges Agent, Lenders and each other Indemnified Person from any and all claims, suits, actions, investigations, proceedings or demands arising
out of or in connection with the Credit Agreement (collectively, "Claims"), whether based in contract, tort, implied or express warranty, strict liability, criminal or civil statute or common law of
any kind or character, known or unknown, which any Borrower or any other Credit Party ever had, now has or might hereafter have against Agent or Lenders which relates, directly or indirectly, to any
acts or omissions of Agent, Lenders or any other Indemnified Person on or prior to the Effective Date, provided, that no Borrower nor any other Credit Party waives any Claim solely to the extent such
Claim relates to Agent's or any Lender's gross negligence or willful misconduct. 

        10.    Fees and Expenses    

        (a)    Amendment Fees.    To induce Agent and the Lenders to enter into this Amendment, Borrowers hereby agree to pay
Agent, for the ratable benefit of the Lenders, an amendment fee in the amount of $125,000.00 in immediately available funds, payable on the Effective Date (the "Amendment
Fee"). 

        (b)    Expenses.    Borrowers hereby reconfirm their obligations pursuant to  Section 11.3 of the Credit Agreement to pay and
reimburse Agent for all reasonable costs and expenses (including, without limitation, reasonable
fees of counsel) incurred in connection with the negotiation, preparation, execution and delivery of this Amendment and all other documents and instruments delivered in connection herewith. 

9

 

        11.    Effectiveness.    

        (a)   Upon
satisfaction in full in the judgment of Agent of each of the following conditions, this Amendment shall be deemed effective as of June 30, 2004 (together
with the date of effectiveness of Paragraph 4 (or each such date, as applicable), the "Effective Date"): 

        (i)    Amendment.    Agent shall have received four (4) original signature pages to this Amendment, duly
executed and delivered by Agent, Requisite Lenders, and in the case of Section 2(a), all Lenders, and each of the Credit Parties. 

        (ii)    Payment of Fees and Expenses.    Borrowers shall have paid to Agent all costs, fees and expenses owing in
connection with this Amendment and the other Loan Documents and due to Agent (including, without limitation, the Amendment Fee and reasonable legal fees and expenses). 

        (iii)    Representations and Warranties.    The representations and warranties of or on behalf of each of the Credit
Parties in this Amendment shall be true and correct on and as of the date hereof and the Effective Date. 

        (b)   The
amendments set forth in Paragraph 4 hereof shall be effective upon satisfaction in full in the judgment of Agent of each of the conditions set forth in
subsection (a) above and each of the following conditions set forth below; provided, that the requirements set forth in subsection
(b)(iii) and (b)(iv) below shall not be required to be satisfied until the dates specified therein; and provided,  further, that failure to comply
with such provisions within such timeframes shall constitute an immediate Event of Default: 

        (i)    Joinder.    Agent shall have received a joinder agreement, in form and substance satisfactory to Agent, duly
executed by (i) IVC pursuant to which, inter alia, IVC joins the Credit Agreement and the other Loan Documents as a US Credit Party, and
(ii) Hall pursuant to which, inter alia, Hall joins the Credit Agreement and the other Loan Documents as a European Credit Party. 

        (ii)    Security Interest and Code Filings.    

        (A)  Each
of IVC and Hall shall have granted a valid first priority perfected security interest (subject to Permitted Encumbrances) in all of its assets (other than, in the
case of IVC, the IVC Mortgaged Property) to secure, in the case of IVC, the Obligations of the Credit Parties, and, in the case of Hall, the Obligations of the European Credit Parties and execute all
documents (including financing statements under the Code (or foreign equivalent) and other applicable documents under the laws of any jurisdiction with respect to the perfection of Liens in form and
substance reasonably acceptable to Agent) as Agent may request in order to perfect its security interest in such assets. 

        (B)  Each
of IVC and Hall shall provide copies of Code (or, in the case of Hall, the foreign equivalent thereof) search reports (or, where not available, such other
equivalent information available and reasonably satisfactory to Agent) listing all effective financing statements (or equivalent information) that name IVC or Hall as debtor, together with copies of
such financing statements (or equivalent information), none of which shall cover the assets of IVC or Hall (other than the IVC Mortgaged Property). 

        (C)    Control Letters.    IVC shall provide Control Letters from (A) all issuers of uncertificated securities
and financial assets held by IVC, (B) all securities intermediaries with respect to all securities accounts and securities entitlements of IVC, and (C) all futures commission agents and
clearing houses with respect to all commodities contracts and commodities accounts held by IVC. 

10

 

        (iii)    Waivers.    Within 60 days after the IVC and Hall Joinder Date, Agent, on behalf of Lenders, shall
have received landlord waivers and consents, bailee letters and mortgagee agreements in form and substance reasonably satisfactory to Agent, in respect of IVC and Hall, and in each case as required
pursuant to  Section 5.9 of the Credit Agreement; provided, however, that in the case of IVC, bailee letters
shall not be required to be delivered in respect of any location at which the value of the collateral owned by IVC and held at such location does not exceed $50,000.00 in the aggregate at any one
time. 

        (iv)    Pledge Amendment.    Agent shall have received a pledge amendment, in form and substance satisfactory to
Agent, pursuant to which (i) Innovations pledges one hundred percent (100%) of the issued and outstanding Stock of IVC (the "IVC Stock") to
Agent, duly executed by an authorized officer of Innovations, and (ii) IVC pledges 66% of the issued and outstanding Stock of Hall (the "Hall
Stock"), duly executed by an authorized officer of IVC. Agent shall have received original certificates representing the IVC Stock pledged by Innovations and the Hall Stock
pledged by IVC. 

        (v)    Cash Management.    Within 60 days after the IVC and Hall Joinder Date, Agent shall have received
tri-party blocked account agreements, in form and substance reasonably satisfactory to Agent, duly executed and delivered by (i) IVC and each bank where IVC has established a
deposit or disbursement account (other than payroll accounts), and (ii) Hall and each bank where Hall has established a deposit or disbursement account (other than payroll accounts), in each
case in accordance with the requirements set forth in Section 1.8 and Annex C of the Credit
Agreement. 

        (vi)    Schedules.    Agent shall have received (x) updated Schedules 3.1, 3.2, 3.6,
3.7, 3.8, 3.15, 3.19 and 5.1 to the Credit Agreement and (y) a revised Exhibit A-1 updated to include
Material Contracts, if any, to which IVC or Hall is a party, each in form and substance satisfactory to Agent. 

        (vii)    Charter and Good Standing.    Agent shall have received a copy of each of (i) IVC's and Hall's charter
documents and all amendments thereto and (ii) good standing certificates or the foreign equivalent and certificates of qualification to conduct business in each jurisdiction where their
respective ownership or lease of property or the conduct of its business requires such qualification, each dated a recent date and certified by the applicable authorized Governmental Authority. 

        (viii)    Bylaws and Resolutions.    Agent shall have received a copy of (i) each of IVC's and Hall's bylaws
(or foreign equivalent thereof) and all amendments thereto, and (ii) resolutions of each of IVC's and Hall's board of directors approving and authorizing the execution, delivery and performance
of the Loan Documents to which IVC or Hall is, or will be a party and the transactions to be consummated in connection therewith, each certified by an authorized officer of each of IVC and Hall as
being in full force and effect without any modification or amendment. 

        (ix)    Incumbency.    Agent shall have received a signature and incumbency certificate of the officers of each of IVC
and Hall, certified by IVC's or Hall's, as applicable, corporate secretary or an assistant secretary as being true, accurate, correct and complete in all respects. 

        (x)    Opinion of Counsel.    Agent shall have received legal opinions of counsel acceptable to Agent (subject to
customary qualifications) which shall provide that the Loan Documents have been duly authorized, executed and delivered by, and are enforceable against each of IVC and Hall and containing such other
opinions as Agent may reasonably request, all in form and substance satisfactory to Agent. 

11

 

        (xi)    Payment of Congress Indebtedness; Bond Satisfaction.    IVC shall provide evidence satisfactory to Agent that
(i) all of its obligations to Congress Financial Corporation under that certain Loan and Security Agreement, dated as of October 16, 2000, between IVC and Congress Financial Corporation,
as amended, as well as all related financing documentation as in effect immediately prior to the Effective Date, will be performed and paid in full and all Liens upon any of the property of IVC or any
other Credit Party in respect thereof shall have terminated immediately upon such payment and (ii) the Bond Satisfaction has been consummated. 

        (xii)    Appointment of Agent for Service of Process.    Agent shall have received evidence that CT Corporation has
been appointed as agent for service of process for each of IVC and Hall. 

        (xiii)    Representations and Warranties.    The representations and warranties of or on behalf of each of the Credit
Parties in this Amendment shall be true and correct on and as of the IVC and Hall Joinder Date. 

        (c)   The
Consent shall be effective on the earlier of the IVC and Hall Joinder Date or the date on which Borrower transfers funds or other assets to IVC or the Bond Trustee
for the purpose of consummating the Bond Satisfaction (the "Bond Satisfaction Date"). It shall constitute an immediate Event of Default if the Bond
Satisfaction Date precedes the IVC and Hall Joinder Date by more than thirty (30) days. 

        12.    GOVERNING LAW.    THIS AMENDMENT SHALL BE GOVERNED BY, AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE
OF NEW YORK. 

        13.    Counterparts.    This Amendment may be executed by the parties hereto on any number of separate counterparts
and all of said counterparts taken together shall be deemed to constitute one and the same instrument. 

12

 

        IN
WITNESS WHEREOF, this Amendment has been duly executed as of the date first written above. 

	 	 	BORROWERS
	

 	
 	

WAMPOLE LABORATORIES, LLC.

INVERNESS MEDICAL (UK) HOLDINGS LIMITED
	

 	
 	

By:	
 	

/s/  ANTHONY J. BERNARDO      
 Name: Anthony J. Bernardo

Title: Duly Authorized Signatory
	 	 	 	 	 

13

 

	

 	
 	
AGENT AND LENDERS
	

 	
 	

GENERAL ELECTRIC CAPITAL CORPORATION,

as Agent and Lender
	

 	
 	

By:	
 	

/s/  ILLEGIBLE       
 Authorized Signatory
	

 	
 	

MERRILL LYNCH CAPITAL,

a division of Merrill Lynch Business Financial Services Inc., as Co-Syndication Agent, Documentation Agent and Lender
	

 	
 	

By:	
 	

/s/  ILLEGIBLE       
 Duly Authorized Signatory
	

 	
 	

UBS SECURITIES LLC,

as Co-Syndication Agent
	

 	
 	

By:	
 	

/s/  DAVID A. JUGE, MANAGING DIRECTOR      
 Duly Authorized Signatory
	

 	
 	

By:	
 	

/s/  OLIVER O. TRUMBO II, DIRECTOR      
 Duly Authorized Signatory
	

 	
 	

UBS AG, CAYMAN ISLANDS BRANCH,

as a Lender
	

 	
 	

By:	
 	

/s/  WILFRED V. SAINT, DIRECTOR BANKING PRODUCTS SERVICES, US      
 Duly Authorized Signatory
	

 	
 	

By:	
 	

/s/  WINSLOWE OGBOURNE, ASSOCIATE DIRECTOR BANKING PRODUCTS SERVICES, US      
 Duly Authorized Signatory

14

 

        The following Persons are signatories to this Amendment in their capacity as Credit Parties and not as Borrowers. 

	 	 	INVERNESS MEDICAL INNOVATIONS, INC.

INVERNESS MEDICAL, INC.

UNIPATH DIAGNOSTICS, INC.

UNIPATH ONLINE, INC.

OSTEX INTERNATIONAL, INC.

INVERNESS MEDICAL INTERNATIONAL HOLDING CORP.

INVERNESS MEDICAL INTERNATIONAL HOLDING CORP. II

UNIPATH LIMITED APPLIED BIOTECH, INC.

FOREFRONT DIAGNOSTICS, INC.

MORPHEUS ACQUISITION CORP.

MORPHEUS ACQUISITION LLC

INVERNESS MEDICAL CANADA INC.

MEDICALE INVERNESS CANADA INC.

INNOVATIONS RESEARCH LLC

ADVANTAGE DIAGNOSTICS CORPORATION
	

 	
 	

By:	
 	

/s/  ANTHONY J. BERNARDO      
 Name: Anthony J. Bernardo

Title: Duly Authorized Signatory
	

 	
 	

ORGENICS INTERNATIONAL HOLDINGS BV

INVERNESS MEDICAL SWITZERLAND LTD

LIAB. CO

UNIPATH DIAGNOSTICS GMBH

CAMBRIDGE DIAGNOSTICS IRELAND LIMITED

PREGYMED GMBH

SCANDINAVIAN MICRO BIODEVICES APS

SELFCARE TECHNOLOGY, INC.

VIVA DIAGNOSTIKA—DIAGNOSTISCHE PRODUKTE—GMBH

DMD, DIENSTLEISTUNGEN & VERTRIEB FUR MEDIZIN UND DIAGNOSTIK GMBH
	

 	
 	

By:	
 	

/s/  PAUL T. HEMPEL      
 Name: Paul T. Hempel

Title: Duly Authorized Signatory

15

ANNEX F (Section 6.10)

to

CREDIT AGREEMENT  

FINANCIAL COVENANTS  

        The Reporting Credit Parties shall not breach or fail to comply with any of the following financial covenants, each of which shall be calculated in accordance
with GAAP consistently applied: 

        (a)    Maximum Capital Expenditures.    

          (i)  Prior
to the IVC and Hall Joinder Date, the Reporting Credit Parties on a consolidated basis shall not make Capital Expenditures during the following periods that
exceed in the aggregate the amounts set forth opposite each of such periods: 

	Period
 
	 	Maximum Capital Expenditures per Period

	October 1, 2003 through December 31, 2003	 	$	5,000,000
	January 1, 2004 through December 31, 2004	 	$	28,500,000
	January 1, 2005 through December 31, 2005	 	$	21,000,000
	January 1, 2006 through December 31, 2006	 	$	21,000,000
	January 1, 2007 through December 31, 2007	 	$	21,000,000

         (ii)  On
and after the IVC and Hall Joinder Date, the Reporting Credit Parties on a consolidated basis shall not make Capital Expenditures during the following periods that
exceed in the aggregate the amounts set forth opposite each of such periods: 

	Period
 
	 	Maximum Capital Expenditures per Period

	October 1, 2003 through December 31, 2003	 	$	5,000,000
	January 1, 2004 through December 31, 2004	 	$	34,000,000
	January 1, 2005 through December 31, 2005	 	$	22,000,000
	January 1, 2006 through December 31, 2006	 	$	22,000,000
	January 1, 2007 through December 31, 2007	 	$	22,000,000

        (b)    Minimum Fixed Charge Coverage Ratio.    The Reporting Credit Parties shall have on a
consolidated basis at the end of each Fiscal Quarter set forth below, a Fixed Charge Coverage Ratio for the 12-month period then ended (or with respect to the Fiscal Quarters ending on or
before June 30, 2004, the period commencing on October 1, 2003 and ending on the last day of such Fiscal Quarter) of not less than the following: 

	Fiscal Quarter Ending:
 
	 	Fixed Charge Coverage Ratio:

	December 31, 2003	 	1.20:1.00
	March 31, 2004	 	1.20:1.00
	June 30, 2004	 	1.00:1.00
	September 30, 2004	 	0.80:1.00
	December 31, 2004	 	0.70:1.00
	March 31, 2005	 	0.70:1.00
	June 30, 2005	 	0.80:1.00
	September 30, 2005	 	1.00:1.00
	December 31, 2005	 	1.20:1.00
	March 31, 2006	 	1.20:1.00
	June 30, 2006	 	1.20:1.00
	September 30, 2006	 	1.20:1.00
	December 31, 2006	 	1.20:1.00
	March 31, 2007	 	1.20:1.00
	June 30, 2007	 	1.20:1.00
	September 20, 2007	 	1.20:1.00
	December 31, 2007	 	1.20:1.00

 

        (c)    Minimum EBITDA.    The Reporting Credit Parties on a consolidated basis shall have, at the
end
of each Fiscal Quarter set forth below, LTM EBITDA of not less than the following: 

	Fiscal Quarter Ending:
 
	 	EBITDA

	December 31, 2003	 	$	46,500,000
	March 31, 2004	 	$	42,000,000
	June 30, 2004	 	$	38,000,000
	September 30, 2004	 	$	30,000,000
	December 31, 2004	 	$	32,000,000
	March 31, 2005	 	$	34,000,000
	June 30, 2005	 	$	40,000,000
	September 30, 2005	 	$	50,000,000
	December 31, 2005	 	$	50,000,000
	March 31, 2006	 	$	55,000,000
	June 30, 2006	 	$	60,000,000
	September 30, 2006	 	$	65,000,000
	December 31, 2006	 	$	70,000,000
	March 31, 2007	 	$	70,000,000
	June 30, 2007	 	$	70,000,000
	September 30, 2007	 	$	70,000,000
	December 31, 2007	 	$	70,000,000

        (d)    Maximum Senior Consolidated Leverage Ratio.    The Reporting Credit Parties, on a consolidated
basis, shall have, at the end of each Fiscal Quarter set forth below, a Senior Consolidated Leverage Ratio as of the last day of such Fiscal Quarter and for the 12-month period then ended
of not more than the following: 

1.20:1.00
for the Fiscal Quarter ending December 31, 2003

1.20:1.00 for the Fiscal Quarter ending March 31, 2004

1.20:1.00 for the Fiscal Quarter ending June 30, 2004

1.20:1.00 for the Fiscal Quarter ending September 30, 2004

1.20:1.00 for the Fiscal Quarter ending December 31, 2004

1.20:1.00 for the Fiscal Quarter ending March 31, 2005

1.20:1.00 for the Fiscal Quarter ending June 30, 2005

1.20:1.00 for the Fiscal Quarter ending September 30, 2005

1.20:1.00 for the Fiscal Quarter ending December 31, 2005

1.00:1.00 for the Fiscal Quarter ending March 31, 2006

1.00:1.00 for the Fiscal Quarter ending June 30, 2006

1.00:1.00 for the Fiscal Quarter ending September 30, 2006

1.00:1.00 for the Fiscal Quarter ending December 31, 2006

1.00:1.00 for the Fiscal Quarter ending March 31, 2007

1.00:1.00 for the Fiscal Quarter ending June 30, 2007

1.00:1.00 for the Fiscal Quarter ending September 30, 2007

1.00:1.00 for the Fiscal Quarter ending December 31, 2007 

        (e)    Maximum Total Leverage Ratio.    On and after the date of the Subordinated Bond Issuance, the Reporting Credit
Parties, on a consolidated basis, shall have, at the end of each Fiscal Quarter set forth below, a Total Leverage Ratio as of the last day of such Fiscal Quarter and for the 12 month period
then ended of not more than the following: 

4.25:1.00
for the Fiscal Quarter ending December 31, 2003

4.25:1.00 for the Fiscal Quarter ending March 31, 2004

4.50:1.00 for the Fiscal Quarter ending June 30, 2004

6.00:1.00 for the Fiscal Quarter ending September 30, 2004

F-2

 

5.75:1.00
for the Fiscal Quarter ending December 31, 2004

5.00:1.00 for the Fiscal Quarter ending March 31, 2005

4.25:1.00 for the Fiscal Quarter ending June 30, 2005

4.25:1.00 for the Fiscal Quarter ending September 30, 2005

4.00:1.00 for the Fiscal Quarter ending December 31, 2005

3.50:1.00 for the Fiscal Quarter ending March 31, 2006

3.50:1.00 for the Fiscal Quarter ending June 30, 2006

3.50:1.00 for the Fiscal Quarter ending September 30, 2006

3.50:1.00 for the Fiscal Quarter ending December 31, 2006

3.00:1.00 for the Fiscal Quarter ending March 31, 2007

3.00:1.00 for the Fiscal Quarter ending June 30, 2007

3.00:1.00 for the Fiscal Quarter ending September 30, 2007

3.00:1.00 for the Fiscal Quarter ending December 31, 2007 

        (f)    Minimum Cash.    The Credit Parties, on a consolidated basis, shall have at all times available cash equal to
at least $10,000,000 (or the Equivalent Amount thereof). 

        Unless
otherwise specifically provided herein, any accounting term used in the Agreement shall have the meaning customarily given such term in accordance with GAAP, and all financial
computations hereunder shall be computed in accordance with GAAP consistently applied. That certain items or computations are explicitly modified by the phrase "in accordance with GAAP" shall in no
way be construed to limit the foregoing. If any "Accounting Changes" (as defined below) occur and such changes result in a change in the calculation of the financial covenants, standards or terms used
in the Agreement or any other Loan Document, then the Credit Parties, Agent and Lenders agree to enter into negotiations in order to amend such provisions of the Agreement so as to equitably reflect
such Accounting Changes with the desired result that the criteria for evaluating the Credit Parties' financial condition shall be the same after such Accounting Changes as if such Accounting Changes
had not been made; provided, however, that the agreement of Requisite Lenders to any required amendments of such provisions shall be sufficient to bind all Lenders. "Accounting Changes" means
(i) changes in accounting principles required by the promulgation of any rule, regulation, pronouncement or opinion by the Financial Accounting Standards Board of the American Institute of
Certified Public Accountants (or successor thereto or any agency with similar functions), (ii) changes in accounting principles concurred in by Innovations' certified public accountants;
(iii) purchase accounting adjustments under A.P.B. 16 or 17 and EITF 88-16, and the application of the accounting principles set forth in FASB 109, including the establishment of
reserves pursuant thereto and any subsequent reversal (in whole or in part) of such reserves; and (iv) the reversal of any reserves established as a result of purchase accounting adjustments.
All such adjustments resulting from expenditures made subsequent to the Closing Date (including capitalization of costs and expenses or payment of
pre-Closing Date liabilities) shall be treated as expenses in the period the expenditures are made and deducted as part of the calculation of EBITDA in such period. If Agent, Credit
Parties and Requisite Lenders agree upon the required amendments, then after appropriate amendments have been executed and the underlying Accounting Change with respect thereto has been implemented,
any reference to GAAP contained in the Agreement or in any other Loan Document shall, only to the extent of such Accounting Change, refer to GAAP, consistently applied after giving effect to the
implementation of such Accounting Change. If Agent, Credit Parties and Requisite Lenders cannot agree upon the required amendments within 30 days following the date of implementation of any
Accounting Change, then all Financial Statements delivered and all calculations of financial covenants and other standards and terms in accordance with the Agreement and the other Loan Documents shall
be prepared, delivered and made without regard to the underlying Accounting Change. For purposes of Section 8.1, a breach of a Financial Covenant contained in this Annex F shall be deemed to
have occurred as of any date of determination by Agent or as of the last day of any specified measurement period, regardless of when the Financial Statements reflecting such breach are delivered to
Agent. 

F-3

QuickLinks

EXHIBIT 10.2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00070-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00070-of-00352.parquet"}]]